LICWINKO v. CELGENE CORPORATION

CourtDistrict Court, D. New Jersey
DecidedJuly 8, 2020
Docket3:20-cv-00255
StatusUnknown

This text of LICWINKO v. CELGENE CORPORATION (LICWINKO v. CELGENE CORPORATION) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
LICWINKO v. CELGENE CORPORATION, (D.N.J. 2020).

Opinion

*NOT FOR PUBLICATION*

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

: CAROLINE LICWINKO, : : Plaintiff, : Civil Action No. 20-00255 : v. : : OPINION CELGENE CORPORATION and : AMY KLEIN, : : Defendants. : :

WOLFSON, Chief Judge: Presently before the Court is a motion by defendant Amy Klein (“Klein”) to dismiss the Complaint filed by plaintiff Caroline Licwinko (“Plaintiff”) for failure to state a claim, pursuant to Fed. R. Civ. P. 12(b)(6). The instant motion arises out of the termination of Plaintiff’s employment with defendant Celgene Corporation1 (“Celgene”) (Klein and Celgene collectively, “Defendants”), after Plaintiff took a leave of absence to care for herself and her child, who was the victim of a sexually violent offense. Plaintiff’s Complaint raises claims under the New Jersey Family Leave Act (“NJFLA”), the Family and Medical Leave Act (“FMLA”), the New Jersey Law Against Discrimination (“LAD”), the New Jersey Security and Financial Empowerment Act (“SAFE Act”), and a Pierce2 public policy claim. For the reasons that follow, Defendant Klein’s motion to dismiss is GRANTED in part as follows: Plaintiff’s FMLA and LAD claims are dismissed without prejudice. Plaintiff is given

1 Celgene has not joined in Klein’s motion to dismiss. 2 Pierce v. Ortho Pharm. Corp., 84 N.J. 58 (1980) establishes a common law cause of action for wrongful discharge when the discharge is contrary to a clear mandate of public policy. leave to file an amended complaint, by July 24, 2020, to cure the deficiencies outlined in this Opinion. Plaintiff’s Pierce and NJFLA claims are dismissed with prejudice. However, Defendant’s motion to dismiss Plaintiff’s SAFE Act claim is terminated, pending additional briefing on the issue of waiver; Defendants, both Celgene and Klein, are directed to file their

briefing by no later than July 22, 2020, and Plaintiff shall file her response by no later than August 5, 2020. I. FACTUAL BACKGROUND AND PROCEDURAL HISTORY The facts of this matter, as set forth in Plaintiff’s Complaint and taken as true by this Court on the motion to dismiss, are as follows. Plaintiff began working for Celgene on July 1, 2014 and was recognized for “outstanding” performance until 2018. (Compl., ¶¶ 14, 19-20.) In March 2018, Plaintiff learned that her young child was the victim of a sexually violent offense, which has resulted in criminal investigations. (Id., ¶ 22.) As a result, Plaintiff was allegedly diagnosed with an acute stress reaction which required psychotherapy, professional treatment, and medication. (Id., ¶ 24.) Subsequently, Plaintiff requested a leave of absence to seek medical attention and

psychological counseling for herself and her child, and to participate in criminal court proceedings. (Id., ¶ 23.) Plaintiff obtained approval from Celgene and Klein, a member of Celgene’s upper management, to take a leave of absence, which spanned from March 8, 2018 to May 6, 2018. (Id., ¶¶ 26-27.) Celgene recognized and processed this leave of absence as FMLA leave. (Id., ¶ 28.) Plaintiff alleges that upon her return from leave, Defendants began harassing her, treating her differently, and fabricating new issues related to Plaintiff’s employment and performance. (Id., ¶ 31.) On May 11, 2018, on her first week back at work, Plaintiff was purportedly summoned to attend a meeting at Celgene’s corporate headquarters with Klein and other Celgene personnel. (Id., ¶ 32.) During the meeting, Defendants allegedly raised issues and unfounded accusations for the first time against Plaintiff. (Id., ¶ 34.) Defendants reportedly questioned Plaintiff about whether the issues that caused her to take leave had been resolved by asking, “So you’re saying that nothing will affect how you work from here on out?” (Id., ¶¶ 35-36.) Defendants also allegedly asked Plaintiff, “Are you willing to commit to work up to the full expectations of the job? It’s expected

that you work 9 to 5 every day. 9 to 5 every day. Do we have your commitment on that?” (Id., ¶ 38.) Additionally, Celgene management allegedly refused to provide information requested by Plaintiff about what she had missed during her two months of leave. (Id., ¶ 39.) Plaintiff purportedly felt so traumatized by the meeting that she took the rest of the day off, utilizing half a vacation day in order to do so. (Id., ¶ 41.) That same afternoon, Plaintiff received an email from Klein stating that Plaintiff was now required to give advance notice for vacation days. (Id., ¶ 42.) From that point on, Klein and other members of Celgene management allegedly ceased communication with Plaintiff and denied her work-related support required on matters necessary to perform her job. (Id., ¶ 43.) Additionally, Celgene allegedly blocked Plaintiff from using her corporate credit card, denying her a tool critical for her work as a sales professional. (Id.,

¶ 47.) On August 20, 2018, Plaintiff notified Defendants that she required additional time off for her and her child’s ongoing medical treatment and appointments. (Id., ¶ 49.) On August 21, 2018, Celgene notified Plaintiff that she was eligible for 3.6 weeks of remaining FMLA leave, and Celgene required Plaintiff to use this FMLA leave to care for her child instead of her vacation, personal, or lunch time. (Id., ¶¶ 51, 53.) Plaintiff intermittently used this remaining FMLA leave two days per week from August 23, 2018 through November 2018. (Id., ¶ 27.) According to Plaintiff, Defendants continued their campaign of discrimination and retaliation by investigating Plaintiff on past events, which had occurred two and a half years earlier. (Id., ¶ 54.) The investigation, which was conducted by outside legal counsel, allegedly did not reveal any evidence of wrongful conduct by Plaintiff. (Id., ¶ 55.) In 2019, an “anonymous tip” prompted Defendants to launch another investigation into alleged wrongdoing by Plaintiff. (Id., ¶ 60.) As in the first investigation, the accusation was eventually determined to be unfounded and unsubstantiated; however, Defendants allegedly continued investigating Plaintiff for months, and

ordered Plaintiff to attend “interrogations” with Celgene’s legal counsel on mere hours’ notice. (Id., ¶¶ 61-63.) On June 25, 2019, Plaintiff, again, requested time off to prepare for criminal court proceedings concerning the sexual violence suffered by her child. (Id., ¶ 66.) Celgene granted the request and acknowledged that it was made pursuant to the New Jersey SAFE Act. (Id., ¶ 67.) Two weeks later, on July 12, 2019, Celgene allegedly “interrogated” Plaintiff on less than a day’s notice and without legal counsel to represent Plaintiff. (Id., ¶ 68.) Despite a lack of evidence to support the unfounded allegations against Plaintiff, Celgene terminated Plaintiff’s employment on August 6, 2019, while Plaintiff was on vacation. (Id., ¶ 69.) Plaintiff filed the present lawsuit against Defendants on December 10, 2019, in New Jersey

state court, asserting claims under the NJFLA, FMLA, LAD, SAFE Act, and Pierce. On January 7, 2020, Defendants removed the matter to this Court. On January 28, 2020, Klein filed the instant motion.3 II. STANDARD OF REVIEW In reviewing a motion to dismiss for failure to state a claim upon which relief can be granted, pursuant to Federal Rule of Civil Procedure 12(b)(6), “courts accept all factual allegations

3 In addition to the claims discussed below, Klein also moved to dismiss Plaintiff’s NJFLA claim on the ground that the statute does not provide for individual liability against supervisors. (Def. Br. at 5-6.) Plaintiff concedes that she cannot locate any case imposing individual supervisor liability under the NJFLA and consents to dismissal of her NFJLA claim against Klein. (Pl. Br.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Santiago v. Warminster Township
629 F.3d 121 (Third Circuit, 2010)
Peter Bistrian v. Troy Levi
696 F.3d 352 (Third Circuit, 2012)
Mary Kasper v. County of Bucks
514 F. App'x 210 (Third Circuit, 2013)
Phillips v. County of Allegheny
515 F.3d 224 (Third Circuit, 2008)
Figueroa v. City of Camden
580 F. Supp. 2d 390 (D. New Jersey, 2008)
Fowler v. UPMC SHADYSIDE
578 F.3d 203 (Third Circuit, 2009)
Bosshard v. Hackensack Univ. Med. Ctr.
783 A.2d 731 (New Jersey Superior Court App Division, 2001)
Cicchetti v. Morris County Sheriff's Office
947 A.2d 626 (Supreme Court of New Jersey, 2008)
Pierce v. Ortho Pharmaceutical Corp.
417 A.2d 505 (Supreme Court of New Jersey, 1980)
Tartaglia v. UBS PaineWebber Inc.
961 A.2d 1167 (Supreme Court of New Jersey, 2008)
Wilson v. Wal-Mart Stores
729 A.2d 1006 (Supreme Court of New Jersey, 1999)
Tarr v. Ciasulli
853 A.2d 921 (Supreme Court of New Jersey, 2004)
Mehlman v. Mobil Oil Corp.
707 A.2d 1000 (Supreme Court of New Jersey, 1998)
Shepherd v. Hunterdon Developmental Center
803 A.2d 611 (Supreme Court of New Jersey, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
LICWINKO v. CELGENE CORPORATION, Counsel Stack Legal Research, https://law.counselstack.com/opinion/licwinko-v-celgene-corporation-njd-2020.